Dataset related to article "Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19"
- Giulio G Stefanini1
- Mauro Chiarito2
- Giuseppe Ferrante2
- Francesco Cannata2
- Elena Azzolini1
- Giacomo Viggiani2
- Andrea De Marco2
- Martina Briani2
- Monica Bocciolone2
- Renato Bragato2
- Elena Corrada2
- Gabriele L Gasparini2
- Manuel Marconi2
- Lorenzo Monti2
- Paolo A Pagnotta2
- Cristina Panico2
- Daniela Pini2
- Damiano Regazzoli2
- Ilaria My2
- Marinos Kallikourdis1
- Michele Ciccarelli2
- Salvatore Badalamenti2
- Alessio Aghemo1
- Bernhard Reimers2
- Gianluigi Condorelli1
- Humanitas COVID-19 Task Force
- 1. IRCCS Humanitas Research Hospital, via Manzoni 56,20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy
- 2. IRCCS Humanitas Research Hospital, via Manzoni 56, 20072 Rozzano (Mi) - Italy
Description
This record contains raw data related to article “Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19"
Objective: Risk stratification is crucial to optimise treatment strategies in patients with COVID-19. We aimed to evaluate the impact on mortality of an early assessment of cardiac biomarkers in patients with COVID-19.
Methods: Humanitas Clinical and Research Hospital (Rozzano-Milan, Lombardy, Italy) is a tertiary centre that has been converted to the management of COVID-19. Patients with confirmed COVID-19 were entered in a dedicated database for cohort observational analyses. Outcomes were stratified according to elevated levels (ie, above the upper level of normal) of high-sensitivity cardiac troponin I (hs-TnI), B-type natriuretic peptide (BNP) or both measured within 24 hours after hospital admission. The primary outcome was all-cause mortality.
Results: A total of 397 consecutive patients with COVID-19 were included up to 1 April 2020. At the time of hospital admission, 208 patients (52.4%) had normal values for cardiac biomarkers, 90 (22.7%) had elevated both hs-TnI and BNP, 59 (14.9%) had elevated only BNP and 40 (10.1%) had elevated only hs-TnI. The rate of mortality was higher in patients with elevated hs-TnI (22.5%, OR 4.35, 95% CI 1.72 to 11.04), BNP (33.9%, OR 7.37, 95% CI 3.53 to 16.75) or both (55.6%, OR 18.75, 95% CI 9.32 to 37.71) as compared with those without elevated cardiac biomarkers (6.25%). A multivariate analysis identified concomitant elevation of both hs-TnI and BNP as a strong independent predictor of all-cause mortality (OR 3.24, 95% CI 1.06 to 9.93).
Conclusions: An early detection of elevated hs-TnI and BNP predicts mortality in patients with COVID-19. Cardiac biomarkers should be systematically assessed in patients with COVID-19 at the time of hospital admission in order to optimise risk stratification.
Files
Restricted
The record is publicly accessible, but files are restricted. Log in to check if you have access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
This set of raw data is accessible under request because they include sensitive data.
Please write your request at biblioteca@humanitas.it
You are currently not logged in. Do you have an account? Log in here
Additional details
Related works
- Is supplement to
- 3281-7312 (ISSN)
- 10.1136/heartjnl-2020-317322 (DOI)